A generic drug is a medication that contains the same active ingredient, in the same dose and form, as a brand-name drug but is sold under its chemical name or a different brand name, typically at a lower price. The key distinction is timing: a generic can only enter the market after the original manufacturer’s patent and exclusivity periods expire, which is why you’ll often see generics appear years after a brand-name drug first became available.
How Generics Compare to Brand-Name Drugs
A generic must deliver the same active ingredient, at the same strength, in the same dosage form (tablet, capsule, liquid), and through the same route (oral, topical, injectable) as the brand-name version. What can differ are the inactive ingredients: the fillers, binders, dyes, and flavorings that hold the pill together or give it a particular color. U.S. trademark law actually requires generics to look different from existing drugs on the market, so a different shape or color is expected and doesn’t signal a difference in quality.
The FDA requires generic manufacturers to submit evidence that every inactive ingredient they use is acceptable and won’t change how the drug performs in your body. So while your generic pill might be a different color or taste slightly different, those cosmetic differences have no effect on the drug’s safety or effectiveness.
The Bioequivalence Standard
Before a generic reaches your pharmacy shelf, the manufacturer must prove the drug is “bioequivalent” to the brand-name version. This means the generic delivers its active ingredient into your bloodstream at essentially the same rate and to the same extent as the original.
The FDA measures this using two main benchmarks: the peak concentration of the drug in your blood, and the total exposure your body gets over time. For a generic to be approved, the statistical confidence interval for both of these measures must fall within 80% to 125% of the brand-name drug’s values. That range sounds wide, but it’s a statistical boundary, not the actual difference. In practice, the average variation between a generic and its brand-name counterpart tends to be much smaller than those outer limits.
This 80-to-125% window is based on a clinical judgment that any drug falling outside this range should not be allowed on the market. The same standard applies regardless of whether the drug treats high blood pressure, diabetes, depression, or any other condition.
Manufacturing and Quality Standards
Generic drugs must be manufactured under the same regulations that govern brand-name production. The FDA’s Current Good Manufacturing Practice requirements apply equally to every drug sold in the United States, whether it’s made domestically or abroad. Facilities producing generics are subject to the same inspection process as those making brand-name medications.
The FDA also monitors drugs after they reach the market, checking that they continue to meet safety and quality standards over time. There is no separate, less rigorous track for generics.
Why Generics Cost Less
The price difference has nothing to do with inferior ingredients or lower quality. Brand-name manufacturers invest heavily in research, clinical trials, and the years-long approval process for a new drug. Generic manufacturers skip most of that: they don’t need to prove the drug works from scratch, only that their version is bioequivalent to one that’s already been proven effective. Lower development costs translate directly into lower prices.
Competition plays a major role too. Once a patent expires, multiple generic manufacturers can enter the market, and prices drop as they compete. According to FDA data, generic drugs approved in 2022 alone saved the U.S. healthcare system $18.9 billion in the 12 months following their approvals. Some products saw price declines of more than 80% compared to their brand-name equivalents. The savings vary widely, though. Of 379 drug products analyzed, about a third saw price reductions under 10%, while a smaller number dropped by 50% or more. The biggest savings tend to come when several generic competitors enter the market for the same drug.
When Generics Become Available
A brand-name drug is protected by patents and exclusivity periods that prevent generics from entering the market for a set number of years. A standard U.S. patent lasts 20 years from the filing date, though the effective period of market protection is shorter because much of that time is spent in development and clinical trials before the drug ever reaches patients.
On top of patents, the FDA grants different types of market exclusivity. A completely new drug (called a new chemical entity) gets five years of exclusivity. Drugs for rare diseases receive seven years. A new use or formulation of an existing drug backed by new clinical studies gets three years. Pediatric studies can add six months to whatever protection already exists. Only after both the patents and exclusivity periods expire can a generic manufacturer submit an application to the FDA.
Do Generics Work as Well?
The large body of evidence supports that generics and brand-name drugs are clinically interchangeable for most patients. A major meta-analysis of 74 randomized trials, including several comparing generic and brand-name blood pressure medications, found no significant differences in adverse event rates between the two. Multiple observational studies using rigorous statistical methods have reached similar conclusions.
That said, the picture isn’t perfectly uniform. One large Canadian study tracked over 136,000 older adults taking certain blood pressure medications and found modestly higher rates of emergency room visits and hospitalizations after generic versions entered the market. The differences were most pronounced for one specific drug where the gap in bioavailability between the generic and brand was largest. The absolute numbers translated to roughly 15 to 40 additional adverse events per 1,000 patients, which is meaningful but still represents a small fraction of users.
For most medications, switching to a generic is straightforward. The areas where clinicians sometimes exercise more caution include drugs with a very narrow therapeutic window, where even small differences in blood levels can matter. If you’re stable on a brand-name version of a medication and notice new symptoms after switching, that’s worth discussing with your pharmacist or prescriber.
How to Verify a Generic Drug
The FDA maintains a resource called the Orange Book that lists all approved drug products along with their therapeutic equivalence ratings. These ratings use a simple coding system. A drug with an “A” code (most commonly “AB”) is considered therapeutically equivalent to the brand-name product and can be substituted at the pharmacy with the full expectation of the same clinical effect and safety profile.
When multiple brand-name versions of the same drug exist, the FDA assigns three-character codes like AB1, AB2, or AB3 to indicate which specific reference product a generic was compared against. A generic coded AB1 is considered interchangeable only with other AB1-coded products under the same heading, not with AB2 or AB3 versions. Your pharmacist uses these codes to determine which generics can be safely substituted for your prescription.
The Orange Book is publicly searchable online, so you can look up any prescription medication and check whether an approved generic equivalent exists, along with its equivalence rating.